Category: Press Releases

Corvia Medical Releases Two-Year Clinical Trial Results Confirming Sustained Benefit and Safety of its Atrial Shunt in Heart Failure Patients

First-ever phase III randomized controlled trial of atrial shunt therapy shows continued promise TEWKSBURY, MA – May 22, 2023 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt […]

Read More

REDUCE LAP-HF II Analyses show 50% of study patients demonstrated significant Clinical Benefit from the Corvia® Atrial Shunt

Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, MA – APRIL 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) […]

Read More

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia® Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy  TEWKSBURY, MA – FEBRUARY 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the Corvia® Atrial Shunt in […]

Read More

Corvia Medical Completes Randomization in REDUCE LAP-HF II Pivotal Trial and Gains FDA Authorization to Provide Continued Access for the Corvia Atrial Shunt

Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, MA – November 17, 2020 — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the […]

Read More

First Japanese Patients Randomized in Corvia Medical’s REDUCE LAP-HF II Global Clinical Trial for Heart Failure

TEWKSBURY, MA – January 13, 2020— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization from the Pharmaceutical and Medical Device Agency (PMDA) in the REDUCE LAP-HF II trial. The Corvia InterAtrial […]

Read More

Corvia Medical’s Interatrial Shunt Device (IASD®) Receives Breakthrough Device Designation For Heart Failure

TEWKSBURY, MA – October 9, 2019— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its InterAtrial Shunt Device (IASD) for heart failure.The IASD is the world’s first transcatheter device […]

Read More